Background
==========

The formation of scar tissue is part of the normal healing process that follows injury to the skin or following surgery, but some individuals are prone to develop hypertrophic scar and keloid. Hypertrophic scar is excessive fibrosis of the skin that is confined to the area of injury and regresses over time. Keloid is excessive fibrosis of the skin that extends beyond the area of injury and does not regress. Severe hypertrophic scar and keloid can also involve the joints and mouth and can occur following severe injury, including burns, and can impair the quality of life for affected individuals. Traditional treatments for hypertrophic scar and keloid include massage therapy, silicone gel treatment, laser therapy, light therapy, and radiotherapy \[[@b1-medscimonit-25-2950]\]. Several emerging treatment options include intralesional cryotherapy, intralesional injection with 5-fluorouracil (5FU), interferon, and bleomycin \[[@b2-medscimonit-25-2950]\].

Treating hypertrophic scar and keloids can be a complicated and difficult procedure. Before treatment, an evaluation of the lesion should be performed to include the size, location, and any pain or tenderness and it is important to understand the expectation of treatment for each patient and to have a multidisciplinary therapeutic approach \[[@b3-medscimonit-25-2950]--[@b5-medscimonit-25-2950]\]. Although several treatments have been used for hypertrophic scar and keloid, there is still no gold standard and for the majority of patients, management is driven by individual clinical experience \[[@b6-medscimonit-25-2950]\]. Intralesional injection with corticosteroid is commonly used but complications such as pain and itch occur after injections \[[@b7-medscimonit-25-2950]\]. Therefore, recent studies have investigated the efficacy of injection with botulinum toxin type A and the inhibition of hypertrophic scars and keloids and the lack of discomfort and other adverse events \[[@b8-medscimonit-25-2950],[@b9-medscimonit-25-2950]\]. However, intralesional botulinum toxin type A has not been routinely used in clinical practice and there have been few multicenter clinical trials with a sufficiently large number of participants to provide the evidence to support its use in the treatment of hypertrophic scar and keloid.

Therefore, the aim of this systematic review and meta-analysis was to compare the effectiveness of intralesional injection of botulinum toxin type A compared placebo with intralesional injection of corticosteroid compared with placebo in patients with hypertrophic scar and keloid.

Material and Methods
====================

Eligibility criteria
--------------------

Randomized controlled trials (RCTs) and prospective controlled trials (PCTs) were identified that compared intralesional injection of botulinum toxin type A with corticosteroid and placebo in hypertrophic scar and keloid. Animal studies, reviews articles, clinical practice guidelines, commentaries, case reports, and published letters were excluded. Low-quality studies with small patient numbers (≤4) were also excluded. Inclusion criteria required that the study compared the clinical effects of intralesional injection with botulinum toxin type A, corticosteroid and placebo, a minimum of one month of follow-up after treatment, and one or more outcomes of interest documented after injection. Exclusion criteria were non-English language and non-Chinese language publications, studies that described only intralesional botulinum toxin type A or corticosteroid or placebo, animal experiments, reviews, clinical practice guidelines, commentaries, case reports and letters, and low-quality studies.

Information sources
-------------------

Six databases were searched, including Web of Science, PubMed, EMBASE, Cochrane Library, WanFang, and China Academic Journals (CNKI) from their inception to March 1, 2019 and without language restriction, using Medical Subject Headings (MeSH) keywords. Only RCTs or PCTs that compared botulinum toxin type A treatment groups with corticosteroid treatment groups or with placebo were identified.

Search strategy
---------------

In accordance with the requirements of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement \[[@b10-medscimonit-25-2950],[@b11-medscimonit-25-2950]\], two different search strategies were used for PubMed. First, the terms searched included "cicatrix" (MeSH term) OR "cicatrix" (All Fields) OR "scar" (All Fields) AND "botulinum toxin" (MeSH term) OR "botulinum" (All Fields) AND "toxins" (All Fields) OR "botulinum toxin" (All Fields) OR "botulinum" (All Fields) AND "toxin" (All Fields) OR "botulinum toxin" (All Fields) AND "adrenal cortex hormones" (MeSH terms) OR "adrenal" (All Fields) AND "cortex" (All Fields) AND "hormones" (All Fields) OR "adrenal cortex hormones" (All Fields) OR "corticosteroid" (All Fields). Second, "cicatrix" (MeSH terms) OR "cicatrix" (All Fields) OR "scar" (All Fields) AND "botulinum toxins" (MeSH terms\] OR "botulinum" (All Fields) AND "toxins" (All Fields) OR "botulinum toxins" (All Fields) OR "botulinum" (All Fields) AND "toxin" (All Fields) OR "botulinum toxin" (All Fields) OR "botulinum toxins" (MeSH terms) OR "botulinum" (All Fields) AND "toxins" (All Fields) OR "botulinum toxins" (All Fields) AND "placebo" (MeSH terms) OR "placebos" (All Fields) OR "placebo" (All Fields).

Study selection
---------------

Two authors reviewed and screened the titles and abstracts of all publications screened. The full text of all possible relevant studies was reviewed. If there were disagreements, a third reviewer was included until a consensus was achieved. Only studies that met the inclusion criteria were included in the final analysis.

Data collection process and risk of bias in individual studies
--------------------------------------------------------------

Data were extracted and assessed independently by the two reviewers and then confirmed by a third reviewer and a fourth more experienced reviewer. The extracted information contained the name of the first author, the publication year, country, number of patients, duration of follow-up, and type of study, the treatment including use and dose, the location of the skin lesions, and the outcome indicators. Also, the Newcastle-Ottawa Scale (NOS) was used to evaluate the risk of bias in individual studies in the meta-analysis \[[@b12-medscimonit-25-2950]\].

Case-control studies were included and were chosen from three aspects, selection (a maximum of 4 items and 4 scores), comparability (a maximum of one item and 2 scores) and exposure (a maximum of 3 items and 3 scores). The total scores were 9 and articles that achieved a score \>5 were regarded as high-quality studies.

Summary measures
----------------

This meta-analysis was conducted using Stata version 15.0 software (Stata Corporation, College Station, TX, USA). The risk ratio (RR) was used to analyze dichotomous data (effective rate) and continuous data, including the Visual Analog Scale (VAS), the Vancouver Scar Scale (VSS), and the width of the scar were analyzed using the weighted mean difference (WMD), both with a 95% confidence interval (CI) \[[@b13-medscimonit-25-2950]\].

Synthesis of results and publication bias across studies
--------------------------------------------------------

To ensure the objectivity and rationality of the meta-analysis, the chi-squared (χ^2^) test was used to assess the study heterogeneity, and I^2^ \>50% indicated statistical heterogeneity, supporting the use of a random effects model (or variance components model). If I^2^ \<50%, the fixed effects model was applied because there was no significant statistical heterogeneity \[[@b14-medscimonit-25-2950]\]. Otherwise, the publication bias of this meta-analysis was evaluated by Egger's test \[[@b15-medscimonit-25-2950]\].

Results
=======

Study selection and risk of bias within studies
-----------------------------------------------

[Figure 1](#f1-medscimonit-25-2950){ref-type="fig"} shows the flow diagram of the systematic review of the literature and selection of studies to compare intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid. The initial literature search identified 3,475 publications. After screening, 15 clinical trials with 639 participants, published between 2006 and 2018 in seven different countries were identified, with a mean follow-up of 6 months, which met the inclusion criteria. All the included studies were full-text publications that were written in English or Chinese and included 11 randomized controlled trials (RCTs) and 4 prospective controlled trials (PCTs) \[[@b16-medscimonit-25-2950]--[@b30-medscimonit-25-2950]\]. [Table 1](#t1-medscimonit-25-2950){ref-type="table"} summarizes the characteristics of the studies identified by the systematic review of the literature and included in the meta-analysis. The risk of bias in individual studies was assessed by the Newcastle-Ottawa Scale (NOS) with a mean score of 7.14 of 9.

Study characteristics
---------------------

Other information extracted from the identified publications included the different sites of the scars, the specific use and dose of botulinum toxin type A, corticosteroid, and placebo in the treatment and control groups, as shown in [Tables 2](#t2-medscimonit-25-2950){ref-type="table"}[](#t3-medscimonit-25-2950){ref-type="table"}--[4](#t4-medscimonit-25-2950){ref-type="table"}. From the included studies, the mean age of the patients was 33.7 years with the most common site for hypertrophic scars and keloids being on the face (55.87%) ([Table 2](#t2-medscimonit-25-2950){ref-type="table"}). Patients and the mode of delivery were similar between the treatment group and control group, with the exception of treatment dose due to the different drug formulations used.

Individual studies and synthesis of results for the primary outcomes
--------------------------------------------------------------------

The Visual Analog Scale (VAS) was commonly used to evaluate the degree of pain and was reflected by the VAS scores \[[@b31-medscimonit-25-2950]\]. Although different hospitals use different types of this scale, the fundamental principle of its use was uniform and included a 10-point scale (0 for no pain, and 10 for severe pain). This advantage of the VAS was that it was easy for patients to use.

Of the 15 included studies, 10 studies assessed VAS after intralesional injection, including 463 participants in total. Data to compare intralesional botulinum toxin type A with placebo were analyzed using a fixed effects model that identified low study heterogeneity (I^2^=10.1%) and there was a significant difference in VAS at about 6 months after injections, with a weighted mean difference (WMD)=1.41 (P\<0.001; 95% CI, 1.21--1.62) ([Figure 2](#f2-medscimonit-25-2950){ref-type="fig"}, [Table 5](#t5-medscimonit-25-2950){ref-type="table"}). After applying the fixed effects model, because of the low heterogeneity (I^2^=0), the forest plot of intralesional botulinum toxin type A compared with intralesional corticosteroid injection showed that there was also a significant difference in the VAS scores, with WMD=−4.30 (P\<0.001, 95% CI, −4.44 to −4.16) ([Figure 3](#f3-medscimonit-25-2950){ref-type="fig"}, [Table 5](#t5-medscimonit-25-2950){ref-type="table"}).

The Vancouver Scar Scale (VSS) contained the four components of melanin pigmentation (0--3 points), scar height (0--4 points), vascularity (0--3 points), and pliability (0--5 points), with a maximal score of 15 points that indicated the most severe scar formation \[[@b32-medscimonit-25-2950]\]. The VSS outcome measure was used in six included studies involving 203 study participants and was measured at the mean follow-up duration of six months after injection. Meta-analysis on the VSS outcome showed a significant difference between the group treated with botulinum toxin type A and the placebo group (WMD=−0.69) (P=0.003; 95% CI, −1.14 to −0.23) and a fixed effects model was used (I^2^=31.4%) ([Figure 4](#f4-medscimonit-25-2950){ref-type="fig"}, [Table 5](#t5-medscimonit-25-2950){ref-type="table"}).

Effective rates for intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid
-----------------------------------------------------------------------------------------------------------------------------

The clinical efficacy of each therapeutic strategy was calculated using the formula: n (effective events)/n (total events). Two studies that included 104 participants reported this outcome. The fixed effects model was used (I^2^=12.2%) and showed a significant difference between injection of intralesional botulinum toxin type A and intralesional injection of corticosteroid, with an RR=0.82 (P=0.012; 95% CI=0.70--0.96) ([Figure 5](#f5-medscimonit-25-2950){ref-type="fig"}, [Table 5](#t5-medscimonit-25-2950){ref-type="table"}).

Width of the scar as an additional outcome
------------------------------------------

The width of the scar was measured in mm to two decimal points. This additional outcome was included in four studies with 164 participants. Meta-analysis to compare intralesional botulinum toxin type A and intralesional placebo used the fixed effects model because of low study heterogeneity (I^2^=0.00%) and a significant difference was identified with (WMD=−0.15) (P=0.000; 95% CI, −0.19 to −0.10) ([Figure 6](#f6-medscimonit-25-2950){ref-type="fig"}, [Table 5](#t5-medscimonit-25-2950){ref-type="table"}). To select the optimal results, this outcome was selected for the longest follow-up duration of six months.

Publication bias across studies
-------------------------------

Because of the limited number of included studies, Egger's test was used to detect the publication bias in the meta-analysis (P=0.883).

Discussion
==========

Scar formation is part of the normal healing process, but hypertrophic scar and keloid are a challenge for plastic surgeons worldwide, not only because they cause functional impairment but because they can have cosmetic effects that can impair social interactions and quality of life \[[@b33-medscimonit-25-2950]\]. Treatments for hypertrophic scar and keloid include physical approaches, laser therapy, light therapy, autologous transfer of adipose tissue, and surgery \[[@b34-medscimonit-25-2950]\]. However, because of incomplete understandings of the mechanism of scarring, each treatment has limitations and comparison and analysis of methods to treat and prevent hypertrophic scar and keloid are required \[[@b35-medscimonit-25-2950]\]. To our knowledge, this was the first systematic review and meta-analysis to compare intralesional botulinum toxin type A with intralesional corticosteroid for the treatment of hypertrophic scar and keloid.

The findings of this meta-analysis showed that patients who received intralesional injections with botulinum toxin type A had a significantly lower incidence and severity of pain compared with patients who received intralesional injections with corticosteroid. Also, the efficacy rate was significantly increased in the botulinum toxin type A group compared with corticosteroid group. When compared with the placebo group, although intralesional injection with botulinum toxin type A was painful for some patients, it achieved significantly improved clinical efficacy which was measured by the Vancouver Scar Scale (VSS) and the width of the scar after injection.

The findings from the meta-analysis appeared to be a real reflection of clinical efficacy of intralesional injection with botulinum toxin type A rather than an artifact of statistical heterogeneity. Also, all the included studies were high-quality studies, which were likely to ensure the quality of the meta-analysis and the result from Egger's test showed that there was no significant publication bias in the meta-analysis.

The findings of this meta-analysis are supported by the findings from previous studies and reviews of the literature. Liu et al. \[[@b36-medscimonit-25-2950]\] and Fanous et al. \[[@b37-medscimonit-25-2950]\], showed botulinum toxin type A inhibited hypertrophic scars and keloids in animal models. A literature review published by Austin et al. \[[@b38-medscimonit-25-2950]\] also showed that botulinum toxin type A had the potential to prevent pathological scar formation in patients with a known individual history or family history of this condition. Li et al. \[[@b39-medscimonit-25-2950]\] and Hao et al. \[[@b40-medscimonit-25-2950]\] reported that botulinum toxin type A could promote the healing of scars, but that the mechanisms require further investigation. However, the number of participants in several previous studies have been small, which has prevented definitive conclusions to be made. However, in the present study, the large patient sample size (\>600 participants) of the meta-analysis adds to the significance of the findings.

However, this study had several limitations. First, analysis of the cost-effectiveness of treatment hypertrophic scar and keloid was not performed, and future studies are needed due to its importance in planning healthcare policy. Botulinum toxin type A and corticosteroid have different costs according to different formulations used. Generally, botulinum toxin type A was more expensive than corticosteroid and was more difficult to source. Second, only four outcomes were assessed in this study, which is likely to have introduced bias into the analysis. The two scales used in this meta-analysis, the VAS and the VSS were both subjective, and there may have been bias introduced from the patient and clinician responses. Third, the majority of included studies were undertaken and reported in Asia (13/15, 86.7%) and the majority of patients were of Asian ethnicity. Therefore, the conclusions from this meta-analysis might not be representative of patients of other ethnicities. Importantly, individuals of African ethnicity are more likely to suffer from hypertrophic scars and keloid than individuals of European ethnicity \[[@b41-medscimonit-25-2950],[@b42-medscimonit-25-2950]\]. However, in this meta-analysis, no individuals of African ethnicity were included because no eligible studies were identified.

Conclusions
===========

The findings from this systematic review of the literature and meta-analysis showed that intralesional injection of botulinum toxin type A was more effective in inhibiting hypertrophic scar and keloid than intralesional injection of corticosteroid or placebo and was also associated with reduced pain following injection. This study has shown that further large-scale, controlled, high-quality studies should be performed to determine the most effective treatment protocols for the use of intralesional injection with botulinum toxin type A in patients with hypertrophic scar and keloid in all ethnic groups.
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###### 

Characteristics of the studies identified by systematic review of the literature and included in the meta-analysis.

  Study first author                                 Year   Country    Treatment   No. of patients   Follow-up (months)   Study type   NOS score   
  -------------------------------------------------- ------ ---------- ----------- ----------------- -------------------- ------------ ----------- ---
  Chang et al. \[[@b16-medscimonit-25-2950]\]        2014   Taiwan     BoNT-A      Placebo                                6            RCT         7
  Chang et al. \[[@b17-medscimonit-25-2950]\]        2014   Taiwan     BoNT-A      Placebo                                6            RCT         8
  Zelken et al. \[[@b18-medscimonit-25-2950]\]       2015   Taiwan     BoNT-A      Placebo                                27           PCT         6
  Pruksapong et al. \[[@b19-medscimonit-25-2950]\]   2007   Thailand   BoNT-A      Placebo           25                   6            RCT         6
  Li et al. \[[@b20-medscimonit-25-2950]\]           2018   China      BoNT-A      Placebo                                6            RCT         7
  Hu et al. \[[@b21-medscimonit-25-2950]\]           2018   China      BoNT-A      Placebo                                6            RCT         7
  Chen et al. \[[@b22-medscimonit-25-2950]\]         2018   China      BoNT-A      Placebo           38                   12--24       PCT         8
  Gassner et al. \[[@b23-medscimonit-25-2950]\]      2006   America    BoNT-A      Placebo           31                   6            PCT         7
  Lee et al. \[[@b24-medscimonit-25-2950]\]          2017   Korea      BoNT-A      Placebo           30                   6            RCT         8
  Ziade et al. \[[@b25-medscimonit-25-2950]\]        2014   France     BoNT-A      Placebo           24                   12           PCT         7
  Wang et al. \[[@b26-medscimonit-25-2950]\]         2009   China      BoNT-A      Corticosteroid    27                   6            RCT         5
  Liu et al. \[[@b27-medscimonit-25-2950]\]          2017   China      BoNT-A      Corticosteroid    80                   6            RCT         6
  Zhao et al. \[[@b28-medscimonit-25-2950]\]         2016   China      BoNT-A      Corticosteroid    86                   5            RCT         5
  Zhang et al. \[[@b29-medscimonit-25-2950]\]        2017   China      BoNT-A      Corticosteroid    100                  1            RCT         6
  Shaarawy et al. \[[@b30-medscimonit-25-2950]\]     2015   Egypt      BoNT-A      Corticosteroid    24                   7            RCT         7

BoNT-A -- botulinum toxin type A; RCT -- randomized controlled trial; PCT -- prospective controlled trial; NOS -- Newcastle-Ottawa Scale.

###### 

Location of the hypertrophic scar or keloid in the studies included in the meta-analysis.

                              Participants with hypertrophic scars or keloids n=639 prevalence   
  -------------- ------------ ------------------------------------------------------------------ --------
  Face (n=357)   Forehead     87                                                                 13.62%
  Ear            32           5.01%                                                              
  Upper lip      117          18.31%                                                             
  Other sites    121          18.94%                                                             
  Trunk (n=90)   Chest wall   55                                                                 8.61%
  Back           9            1.41%                                                              
  Abdomen        26           4.07%                                                              
  Extremity      68           10.64%                                                             
  Not stated     124          19.41%                                                             

###### 

Use and dose of botulinum toxin type A and placebo.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Study first author                                 Year   Country    Use                       Dose                  
  -------------------------------------------------- ------ ---------- ------------------------- --------------------- -------------------
  Chang et al. \[[@b16-medscimonit-25-2950]\]        2014   Taiwan     Intralesional injection   15 units              0.6 ml

  Chang et al. \[[@b17-medscimonit-25-2950]\]        2014   Taiwan     Intralesional injection   6.07±0.64 units       0.17--0.27 ml

  Zelken et al. \[[@b18-medscimonit-25-2950]\]       2015   Taiwan     Intralesional injection   20 units              0.5 ml

  Pruksapong et al. \[[@b19-medscimonit-25-2950]\]   2007   Thailand   Intralesional injection   18.05±5.54 units      1.3--2.46 ml

  Li et al. \[[@b20-medscimonit-25-2950]\]           2018   China      Intralesional injection   5 units/point         0.1 ml/point

  Hu et al. \[[@b21-medscimonit-25-2950]\]           2018   China      Intralesional injection   10 units/cm           0.2 ml/cm

  Chen et al. \[[@b22-medscimonit-25-2950]\]         2018   China      Intralesional injection   1--2 units/point      Not stated

  Gassner et al. \[[@b23-medscimonit-25-2950]\]      2006   America    Intralesional injection   \<2 cm (15 units)\    \<2 cm (0.2 ml)\
                                                                                                 2--4 cm (30 units)\   2--4 cm (0.4 ml)\
                                                                                                 \>4 cm (45 units)     \>4 cm (0.6 ml)

  Lee et al. \[[@b24-medscimonit-25-2950]\]          2017   Korea      Intralesional injection   30 units              1.2 ml

  Ziade et al. \[[@b25-medscimonit-25-2950]\]        2014   France     Intralesional injection   15--40 units          1.5--4 ml
  ----------------------------------------------------------------------------------------------------------------------------------------

BoNT-A -- botulinum toxin type A; NS -- normal saline.

###### 

Use and dose of botulinum toxin type A and corticosteroid.

  Study first author                               Year   Country   Use                       Dose             
  ------------------------------------------------ ------ --------- ------------------------- ---------------- -------------------------------
  Wang et al. \[[@b26-medscimonit-25-2950]\]       2009   China     Intralesional injection   5 units/point    5 units/point
  Liu et al. \[[@b27-medscimonit-25-2950]\]        2017   China     Intralesional injection   5 units/point    5 units/point
  Zhao et al. \[[@b28-medscimonit-25-2950]\]       2016   China     Intralesional injection   ≤55 units/time   0.2 ml/cm^2^
  Zhang et al. \[[@b29-medscimonit-25-2950]\]      2017   China     Intralesional injection   ≤55 units/time   0.2 ml/cm^2^
  Shaarawy et al. \[[@b30-medscimonit-25-2950]\]   2015   Egypt     Intralesional injection   5 units/cm^3^    10 mg/cm^3^ (≤80 mg in total)

BoNT-A -- botulinum toxin type A; NS, normal saline.

###### 

Pooled outcome indicators for patients with hypertrophic scar and keloid.

  Outcomes                               No. of studies   No. of participants   Heterogeneity/I^2^   Analysis model   Q Statistic, P-value   WMD/RR (95% CI)
  -------------------------------------- ---------------- --------------------- -------------------- ---------------- ---------------------- ------------------------
  VAS (botulinum *vs*. place)            7                250                   10.1%                Fixed-effects    \<0.0001               1.41 (1.21--1.62)
  VAS (botulinum *vs*. corticosteroid)   3                213                   0.0%                 Fixed-effects    \<0.0001               −4.30 (−4.44 to −4.16)
  VSS                                    6                203                   31.4%                Fixed-effects    0.003                  −0.69 (−1.14 to −0.23)
  Width of scar                          4                164                   0.0%                 Fixed-effects    0.000                  −0.15 (−0.19 to −0.10)
  Effective rate                         2                104                   12.2%                Fixed-effects    0.012                  0.82 (0.70--0.96)

VAS -- visual analog scale; VSS -- Vancouver Scar Scale; CI -- confidence interval; WMD -- weighted mean difference; RR -- risk ratio.
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